CompaniesAb Initio Biotherapeutics

Ab Initio Biotherapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

1

As Collaborator

3

Total Enrollment

39

By Phase

PHASE1: 4

By Status

COMPLETED: 3NOT_YET_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
NCT02709616
NCT02808364
NCT02808416
NCT06524063
Hover over trial bars to see details

Recent Trials

NCT06524063Lead Sponsor
Targeted Survivin DC Cell Injection for the Treatment of GBM
PHASE1Not yet recruiting
9 participants
Started: Aug 1, 2024 · Completed: Oct 1, 2027
NCT02709616Collaborator
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)
PHASE1Completed
10 participants
Started: Mar 1, 2016 · Completed: Jun 30, 2019
NCT02808364Collaborator
Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
PHASE1Completed
10 participants
Started: Mar 1, 2016 · Completed: Jun 30, 2019
NCT02808416Collaborator
Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)
PHASE1Completed
10 participants
Started: Mar 1, 2016 · Completed: Jun 30, 2019
Related Companies
Ligand Pharmaceuticals
acquired